This isn't the first approval of a Genmab-developed drug, nor is it the first cancer drug that the Danish biotech company is behind. Nonetheless, the approval of tisotumab vedotin, under the commercial name Tivdak, by the US Food and Drug Administration (FDA) is an important stepping stone on the path forward, says Søren Løntoft Hansen, senior analyst at Sydbank.
"The approval of Tivdak is very positive in the way it contributes to the gradually growing portfolio of approved medicines coming from Genmab laboratories, which emphasizes that Genmab is now more than just Darzalex," he tells MedWatch.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Jesper Høiland retires as chief commercial officer of Ascendis Pharma
Former executive vice president of Novo Nordisk, US, Jesper Høiland has decided to step down from his role as global chief commercial officer at Ascendis Pharma.
ALK finds replacement for long-time North America lead
Jorge Alderete, ALK’s president in North America, is leaving the firm after 23 years. He will be replaced by Hans Lindeberg, ALK’s current head of the Nordic region.
Monkeypox vaccine attracts interest for Bavarian as virus spreads
Bavarian, which signed a supply contract with an unnamed European country last week, reports it is in dialog with several countries, some yet to be affected, concerning the firm’s monkeypox vaccine.
Almirall announces Danish launch of MC2 Therapeutics-developed psoriasis cream
Almirall is launching psoriasis cream Wynzora in Denmark. The treatment has been inlicensed from Danish firm MC2 Therapeutics, where the CEO says ”it is a special feeling” to see Wynzora launched in its home country.
Former Ambu CEO's equity investments end in USD 2m losses
Juan Jose Gonzalez, who was the CEO of medtech firm Ambu until very recently, has lost just over DKK 16m (USD 2.3m) before taxes on his share purchases.
Communications Consultant 
Director Global Engineering 
Clinical Trial Administrator 
Innovation Project Manager, Display Unit 
Clinical Trial Manager 
Production Director 
Client Talent Acquisition Specialist 
Nordic Medical Affairs Manager 
(Senior) Drug Substance Specialist 
2 Sales Representatives and Product Specialists 
Key Account Manager, Europe and Asia 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Laboratory technician for process development and clinical manufacturing 
Biomarker Operations Lead 
Account Manager 
System Sales Development Consultant - Investment Projects, Merck Millipore 
IRT Manager, Clinical Drug Supply